BR0102252B1 - Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso - Google Patents

Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Info

Publication number: BR0102252B1
Authority: BR; Brazil
Prior art keywords: angiotensin; pharmaceutical composition; controlled release; receptor antagonist; release system
Prior art date: 2001-04-10

Application number

BRPI0102252-0B1A

Other languages

English (en)

Other versions

BR0102252A (pt

Inventor

Millan Ruben Dario Sinisterra

Paula Washington Xavier De

Dos Santos Robson Augusto Souza

Frederic Jean Georges Frezard

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-10

Filing date

2001-04-10

Publication date

2013-10-22

2001-04-10 Application filed filed Critical

2001-04-10 Priority to BRPI0102252-0B1A priority Critical patent/BR0102252B1/pt

2002-04-09 Priority to EP02713951A priority patent/EP1389106A1/en

2002-04-09 Priority to PCT/BR2002/000051 priority patent/WO2002080910A1/en

2002-04-09 Priority to JP2002578949A priority patent/JP4439814B2/ja

2002-04-09 Priority to CA002444145A priority patent/CA2444145C/en

2002-04-09 Priority to US10/474,640 priority patent/US7858597B2/en

2002-04-09 Priority to CN028106814A priority patent/CN1523985B/zh

2003-01-21 Publication of BR0102252A publication Critical patent/BR0102252A/pt

2007-10-31 Priority to US11/980,345 priority patent/US20080108575A1/en

2009-11-30 Priority to JP2009272002A priority patent/JP2010047611A/ja

2010-12-23 Priority to US12/977,402 priority patent/US8293723B2/en

2012-10-22 Priority to US13/656,941 priority patent/US20130164341A1/en

2013-10-22 Publication of BR0102252B1 publication Critical patent/BR0102252B1/pt

Links

102000005862 Angiotensin II Human genes 0.000 title 1
101800000733 Angiotensin-2 Proteins 0.000 title 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title 1
239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title 1
229950006323 angiotensin ii Drugs 0.000 title 1
238000013270 controlled release Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0102252-0B1A 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso BR0102252B1 (pt)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
BRPI0102252-0B1A BR0102252B1 (pt)	2001-04-10	2001-04-10	Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US10/474,640 US7858597B2 (en)	2001-04-10	2002-04-09	Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
PCT/BR2002/000051 WO2002080910A1 (en)	2001-04-10	2002-04-09	Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
JP2002578949A JP4439814B2 (ja)	2001-04-10	2002-04-09	動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンｉｉａｔ１受容体拮抗薬製剤の調製
CA002444145A CA2444145C (en)	2001-04-10	2002-04-09	Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illness and its complications
EP02713951A EP1389106A1 (en)	2001-04-10	2002-04-09	Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
CN028106814A CN1523985B (zh)	2001-04-10	2002-04-09	用于治疗高动脉压、其它心血管疾病和它的并发症的血管紧张素iiat1受体拮抗剂的制剂的制备
US11/980,345 US20080108575A1 (en)	2001-04-10	2007-10-31	Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
JP2009272002A JP2010047611A (ja)	2001-04-10	2009-11-30	動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンｉｉａｔ１受容体拮抗薬製剤の調製
US12/977,402 US8293723B2 (en)	2001-04-10	2010-12-23	Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
US13/656,941 US20130164341A1 (en)	2001-04-10	2012-10-22	Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
BRPI0102252-0B1A BR0102252B1 (pt)	2001-04-10	2001-04-10	Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Publications (2)

Publication Number	Publication Date
BR0102252A BR0102252A (pt)	2003-01-21
BR0102252B1 true BR0102252B1 (pt)	2013-10-22

Family

ID=3947403

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0102252-0B1A BR0102252B1 (pt)	2001-04-10	2001-04-10	Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Country Status (7)

Country	Link
US (4)	US7858597B2 (pt)
EP (1)	EP1389106A1 (pt)
JP (2)	JP4439814B2 (pt)
CN (1)	CN1523985B (pt)
BR (1)	BR0102252B1 (pt)
CA (1)	CA2444145C (pt)
WO (1)	WO2002080910A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0102252B1 (pt) *	2001-04-10	2013-10-22		Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
BRPI0105509B8 (pt) *	2001-11-05	2021-05-25	Univ Minas Gerais	formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
BRPI0309142C1 (pt)	2002-04-09	2021-05-25	Flamel Ireland Ltd	suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
AU2003246791A1 (en)	2002-04-09	2003-10-20	Flamel Technologies	Oral suspension of amoxicillin capsules
EP1474417B1 (en)	2002-04-29	2006-03-22	Teva Pharmaceutical Industries Ltd.	Processes for preparing losartan and losartan potassium
KR100554156B1 (ko)	2003-07-26	2006-02-22	학교법인 포항공과대학교	쿠커비투릴 유도체가 응집되어 형성된 나노 입자, 그 나노입자에 약물이 담지된 약제학적 조성물, 및 이들의 제조방법
HRP20031029A2 (en) *	2003-12-12	2005-08-31	Belupo - Lijekovi I Kozmetika D.D.	Process for production of inclusion complexes of valsartan with?-cylodextrin
EP1850835A1 (fr) *	2005-02-21	2007-11-07	Flamel Technologies	Forme pharmaceutique orale de losartan
FR2884145A1 (fr) *	2005-04-06	2006-10-13	Flamel Technologies Sa	Forme pharmaceutique orale de losartan
FR2882260A1 (fr) *	2005-02-21	2006-08-25	Flamel Technologies Sa	Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
US8653031B2 (en) *	2006-10-30	2014-02-18	Universidade Federal De Minas Gerais	Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
ES2454741T3 (es)	2007-01-26	2014-04-11	Universidade Federal De Minas Gerais - Ufmg	Composiciones farmac�uticas y m�todos para tratar la disfunci�n er�ctil
JP2011500577A (ja) *	2007-10-09	2011-01-06	ノバルティスアーゲー	バルサルタンの医薬製剤
BRPI0800585B8 (pt)	2008-02-13	2021-05-25	Univ Minas Gerais	composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
BR102012009317B1 (pt) *	2012-04-20	2022-05-31	Universidade Federal De Minas Gerais - Ufmg	Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
EP3373978A4 (en) *	2015-11-12	2019-06-26	Graybug Vision, Inc.	AGGREGATION OF MICROPARTICLES FOR THERAPY
BR112019019452A2 (pt)	2017-03-23	2020-04-14	Graybug Vision Inc	composto, e, uso de um composto
CA3057875A1 (en)	2017-05-10	2018-11-15	Graybug Vision, Inc.	Extended release microparticles and suspensions thereof for medical therapy
CN115175664A (zh) *	2020-03-25	2022-10-11	耶路撒冷希伯来大学伊森姆研究发展有限公司	包含ati受体阻滞剂的脂质体制剂及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5671073A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	Imidazole derivative
JPS6025967A (ja)	1983-07-21	1985-02-08	Eisai Co Ltd	トリパミド包接化合物
US4576958A (en)	1984-01-23	1986-03-18	E. I. Du Pont De Nemours And Company	Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US4666705A (en) *	1985-06-03	1987-05-19	E. R. Squibb & Sons, Inc.	Controlled release formulation
US5256687A (en)	1985-09-09	1993-10-26	Hoechst Aktiengesellschaft	Pharmaceutical composition for the treatment of high blood pressure
GB8613688D0 (en) *	1986-06-05	1986-07-09	Euro Celtique Sa	Pharmaceutical composition
US5138069A (en)	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
CA1334092C (en) *	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
DK406686D0 (da)	1986-08-26	1986-08-26	Hans Bundgaard	Carboxylsyrederivater
US5210079A (en)	1988-01-07	1993-05-11	E. I. Du Pont De Nemours And Company	Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
GB8911854D0 (en)	1989-05-23	1989-07-12	Ici Plc	Heterocyclic compounds
US5064825A (en)	1989-06-01	1991-11-12	Merck & Co., Inc.	Angiotensin ii antagonists
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03275617A (ja) *	1990-03-22	1991-12-06	Teikoku Seiyaku Co Ltd	サイクロデキストリン類包接生理活性物質含有ポリ乳酸類マイクロスフェア及びその製造方法
IL100917A0 (en) *	1991-02-16	1992-11-15	Fisons Plc	Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
HU209658B (en) *	1992-02-21	1994-10-28	Cyclolab Kft	Process for producing cyklodextrin inclusion compexes of fatty acids and their alkalimetal salts, as well as aqueous solutions of the complexes, and microbiological culture medium containing the complexes
AT399718B (de)	1992-04-16	1995-07-25	Lek Tovarna Farmacevtskih	Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5472954A (en) *	1992-07-14	1995-12-05	Cyclops H.F.	Cyclodextrin complexation
US5266583A (en)	1992-09-01	1993-11-30	Merck & Co., Inc.	Angitotensin II antagonist
JP3459421B2 (ja) *	1992-12-23	2003-10-20	サイテックソチエタレスポンサビリタリミテ	調節された開放医薬形の調製法及びそのようにして得られた医薬形
AU6818094A (en) *	1993-04-22	1994-11-08	Depotech Corporation	Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
BE1008307A3 (fr) *	1994-06-16	1996-04-02	Europharmaceuticals Sa	Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5728402A (en)	1994-11-16	1998-03-17	Andrx Pharmaceuticals Inc.	Controlled release formulation of captopril or a prodrug of captopril
US5834432A (en)	1995-06-06	1998-11-10	The University Of Southern California	Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv)	1995-06-19	1995-06-19	Astra Ab	Novel medical use
US6087386A (en)	1996-06-24	2000-07-11	Merck & Co., Inc.	Composition of enalapril and losartan
ES2173433T3 (es)	1996-10-29	2002-10-16	Merck & Co Inc	Procedimiento para la cristalizacion de losartan.
US5916883A (en)	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
IT1295405B1 (it)	1997-09-30	1999-05-12	Merck Sharp & Dohme Italia S P	Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JPH11315034A (ja) *	1998-03-04	1999-11-16	Takeda Chem Ind Ltd	アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
ES2154191B1 (es)	1998-11-24	2001-10-16	Ferrer Int	Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
FR2787330A1 (fr)	1998-12-18	2000-06-23	Sanofi Sa	Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
AU2573800A (en)	1999-02-19	2000-09-04	Takeda Chemical Industries Ltd.	Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
US6383471B1 (en) *	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6178349B1 (en)	1999-04-15	2001-01-23	Medtronic, Inc.	Drug delivery neural stimulation device for treatment of cardiovascular disorders
IT1307265B1 (it)	1999-08-09	2001-10-30	P F C Italiana Srl Speciality	Procedimento per la preparazione di prodotti intermedi nella sintesidi lisinopril.
BR0102252B1 (pt) *	2001-04-10	2013-10-22		Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

2001
- 2001-04-10 BR BRPI0102252-0B1A patent/BR0102252B1/pt not_active IP Right Cessation
2002
- 2002-04-09 CN CN028106814A patent/CN1523985B/zh not_active Expired - Fee Related
- 2002-04-09 EP EP02713951A patent/EP1389106A1/en not_active Withdrawn
- 2002-04-09 CA CA002444145A patent/CA2444145C/en not_active Expired - Fee Related
- 2002-04-09 WO PCT/BR2002/000051 patent/WO2002080910A1/en not_active Ceased
- 2002-04-09 JP JP2002578949A patent/JP4439814B2/ja not_active Expired - Fee Related
- 2002-04-09 US US10/474,640 patent/US7858597B2/en not_active Expired - Fee Related
2007
- 2007-10-31 US US11/980,345 patent/US20080108575A1/en not_active Abandoned
2009
- 2009-11-30 JP JP2009272002A patent/JP2010047611A/ja active Pending
2010
- 2010-12-23 US US12/977,402 patent/US8293723B2/en not_active Expired - Fee Related
2012
- 2012-10-22 US US13/656,941 patent/US20130164341A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR0102252A (pt)	2003-01-21
JP4439814B2 (ja)	2010-03-24
CN1523985B (zh)	2010-05-12
CA2444145C (en)	2009-11-10
JP2004525167A (ja)	2004-08-19
US20080108575A1 (en)	2008-05-08
CN1523985A (zh)	2004-08-25
US8293723B2 (en)	2012-10-23
CA2444145A1 (en)	2002-10-17
US20040171584A1 (en)	2004-09-02
US20110091541A1 (en)	2011-04-21
US7858597B2 (en)	2010-12-28
JP2010047611A (ja)	2010-03-04
WO2002080910A1 (en)	2002-10-17
US20130164341A1 (en)	2013-06-27
EP1389106A1 (en)	2004-02-18

Publication	Publication Date	Title
BR0102252B1 (pt)	2013-10-22	Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
BRPI0212137A2 (pt)	2016-06-28	diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas
HUP0303081A3 (en)	2009-03-30	Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
NO20052496D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20052285D0 (no)	2005-05-10	Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
AR028372A1 (es)	2003-05-07	Dispositivos de administracion de drogas de liberacion sostenida, metodos de uso y metodos de fabricacion de los mismos
PT1303261E (pt)	2005-06-30	Sistema para administracao de drogas auto-emulsionaveis, para drogas lipofilas extremamente insoluveis em agua
DE60135273D1 (de)	2008-09-25	Geschmacksmaskierte pharmazeutische Partikel
DK1095025T3 (da)	2003-04-07	Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
PT102854A (pt)	2003-09-30	Sistema de aplicacao de medicamento bioadesivo
EE200300327A (et)	2003-10-15	Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
ATE355271T1 (de)	2006-03-15	Pharmazeutische zusammensetzung
MXPA02004770A (es)	2003-10-14	Composiciones terapeuticas y metodos para su uso.
HN2002000150A (es)	2002-09-13	Agentes antibacteriano
EE200300048A (et)	2004-12-15	Bensimidasooli derivaadid, nende valmistamine ja terapeutiline kasutamine
PT1237559E (pt)	2006-10-31	Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano
NO20024194L (no)	2002-09-03	Nytt selvemulgerende legemiddelavleveringssystem
AR028588A1 (es)	2003-05-14	Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y uso
ATE366128T1 (de)	2007-07-15	Pharmazeutische zusammensetzung
ECSP066486A (es)	2006-10-10	Antagonistas de receptores de acetilcolina muscarínicos ii
NO20014224D0 (no)	2001-08-31	4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
PT9636T (pt)	2002-01-30	Sistema giratorio interligado com suspensao incorporada para carrinhos de bebe
ES1047330Y (es)	2001-08-16	Pilar esferico perfeccionado para retencion de sobredentaduras.
NO20052491D0 (no)	2005-05-23	Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme
DK1157014T3 (da)	2005-12-27	Polycykliske 2-amino-dihydrothiazolsystemer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler

Legal Events

Date	Code	Title	Description
2009-12-29	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-12-29	B15K	Others concerning applications: alteration of classification	Free format text: ALTERADA DA INT.CL: A61P 9/12, A61P 9/00, A61K 31/724 Ipc: A61K 47/40 (2009.01), A61K 47/30 (2009.01), A61K 9
2010-06-08	B15V	Prolongation of time limit allowed	Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 38 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.
2010-11-03	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2011-06-21	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2012-02-07	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2013-01-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2013-08-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2013-09-10	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2013-10-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2013, OBSERVADAS AS CONDICOES LEGAIS.
2020-06-16	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 19A ANUIDADE